Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies
Stock Information for Sorrento Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.